Key result
Therapeutic plasma exchange restores platelets and halts thrombosis in a patient with refractory autoimmune HIT.
Case Report (n=1)
Therapeutic plasma exchange may be an effective treatment for refractory autoimmune heparin-induced thrombocytopenia by targeting pathogenic heparin-independent anti-PF4 antibodies.
Answers are grounded in this paper and cite their sources.
Therapeutic plasma exchange merits evaluation in refractory autoimmune HIT; single-case evidence leaves open need for prospective confirmation.
Autoimmune heparin-induced thrombocytopenia (aHIT) is a severe subtype of heparin-induced thrombocytopenia characterized by persistent thrombocytopenia and prothrombotic condition, even though anticoagulation with heparin has been discontinued. Here, we report on a patient with a previous history of aHIT where reexposure to heparin during cardiac surgery resulted in recurrent aHIT with pulmonary embolism. Alternative anticoagulants, as well as high-dose intravenous immunoglobulin, were ineffective, and only multiple cycles of therapeutic plasma exchange restored platelet counts and prevented further thrombosis progression. The therapy was guided by an ex vivo model of antiplatelet factor 4 (PF4)-mediated thrombosis that showed accurate performance in predicting the clinical outcome. Most importantly, the ability to induce thrombus formation was mainly caused by anti-PF4 (heparin-independent) antibodies. Our paper provides the first description of recurrent aHIT with translational evidence that pathogenic heparin-independent anti-PF4 antibodies can be specifically targeted by therapeutic plasma exchange, emphasizing the clinical use in refractory cases of aHIT.
No takes yet. Share an insight, caveat, or question.
Zlamal et al. (2025) conducted a case report in Autoimmune heparin-induced thrombocytopenia (aHIT) (n=1). Therapeutic plasma exchange was evaluated on Restoration of platelet counts and prevention of further thrombosis progression. Multiple cycles of therapeutic plasma exchange successfully restored platelet counts and prevented thrombosis progression in a patient with refractory recurrent autoimmune heparin-induced thrombocytopenia.
Synapse has enriched 10 related papers. Consider them for comparative context: